Lesson for the clinical nephrologist: glucagon-like peptide-1 receptor agonists (GLP-1 RA) in a patient with obesity and diabetic kidney disease on peritoneal dialysis
Authors:
- 14 March 2025
- journal article
- lessons for-the-clinical-nephrologist
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 38 (3) , 1123-1125
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025Diabetes Care, 2024
- Semaglutide in patients with kidney failure and obesity undergoing dialysis and wishing to be transplanted: A prospective, observational, open‐label studyDiabetes, Obesity and Metabolism, 2024
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 DiabetesNew England Journal of Medicine, 2024
- Case report of the successful use of semaglutide to achieve target BMI prior to renal transplant in two patients with end‐stage‐kidney‐diseaseNephrology, 2024
- Semaglutide for treatment of obesity in hemodialysis patients waiting for a kidney transplant: new hope?Clinical Kidney Journal, 2022
- Peritoneal Dialysis in the Obese PatientClinical Journal of the American Society of Nephrology, 2019
- Sodium toxicity in peritoneal dialysis: mechanisms and “solutions”Journal Of Nephrology, 2019
- Metabolic syndrome and obesity in peritoneal dialysisKidney Research and Clinical Practice, 2016
- The role of obesity in the pathogenesis of hypertensionNature Clinical Practice Nephrology, 2008